{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:50:46Z","timestamp":1790704246207,"version":"4.1.0"},"reference-count":216,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Portuguese Foundation for Science and Technology (FCT)","award":["SFRH\/BPD\/66288\/2009"],"award-info":[{"award-number":["SFRH\/BPD\/66288\/2009"]}]},{"name":"Portuguese Foundation for Science and Technology (FCT)","award":["SFRH\/BD\/103571\/2014"],"award-info":[{"award-number":["SFRH\/BD\/103571\/2014"]}]},{"name":"Portuguese Foundation for Science and Technology (FCT)","award":["SFRH\/BDP\/101827\/2014"],"award-info":[{"award-number":["SFRH\/BDP\/101827\/2014"]}]},{"name":"European Social Fund (ESF)"},{"name":"European Regional Development Fund (ERDF)"},{"name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia (FCT)","award":["PEst-C\/SAU\/LA0002\/2013"],"award-info":[{"award-number":["PEst-C\/SAU\/LA0002\/2013"]}]},{"name":"North Portugal Regional Operational Programme","award":["SAESCTN-PIIC&DT\/2011"],"award-info":[{"award-number":["SAESCTN-PIIC&DT\/2011"]}]},{"name":"Research Group for Digestive Cancer (Portugal)"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1016\/j.jconrel.2015.05.003","type":"journal-article","created":{"date-parts":[[2015,5,6]],"date-time":"2015-05-06T16:47:55Z","timestamp":1430930875000},"page":"288-307","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":85,"special_numbering":"C","title":["New trends in guided nanotherapies for digestive cancers: A systematic review"],"prefix":"10.1016","volume":"209","author":[{"given":"Elisabete","family":"Fernandes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0097-6148","authenticated-orcid":false,"given":"Jos\u00e9 Alexandre","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peixoto","family":"Andreia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lima","family":"Lu\u00eds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9rgio","family":"Barroso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Sarmento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00facio Lara","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2015.05.003_bb0005","series-title":"GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11","first-page":"2012","author":"Ferlay","year":"2012"},{"key":"10.1016\/j.jconrel.2015.05.003_bb0010","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1007\/s00104-013-2598-5","article-title":"Limitations of surgery for cancer of the upper gastrointestinal tract","volume":"85","author":"Karakas","year":"2014","journal-title":"Chirurg"},{"key":"10.1016\/j.jconrel.2015.05.003_bb0015","doi-asserted-by":"crossref","first-page":"395","DOI":"10.3322\/caac.21199","article-title":"Nanooncology: the future of cancer diagnosis and therapy","volume":"63","author":"Thakor","year":"2013","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0020","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.2147\/OTT.S66502","article-title":"Tumor heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectives","volume":"7","author":"Cheng","year":"2014","journal-title":"Onco Targets Ther."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0025","article-title":"Mechanism-based cancer therapy: resistance to therapy, therapy for resistance","author":"Ramos","year":"2014","journal-title":"Oncogene"},{"key":"10.1016\/j.jconrel.2015.05.003_bb0030","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.molonc.2014.06.005","article-title":"Tumour heterogeneity and the evolution of polyclonal drug resistance","volume":"8","author":"Burrell","year":"2014","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0035","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/j.bcp.2013.02.017","article-title":"Molecular aspects of cancer cell resistance to chemotherapy","volume":"85","author":"Rebucci","year":"2013","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0040","doi-asserted-by":"crossref","first-page":"268","DOI":"10.2174\/156800910791190175","article-title":"Epithelial mesenchymal transition and cancer stem cell-like phenotypes facilitate chemoresistance in recurrent ovarian cancer","volume":"10","author":"Ahmed","year":"2010","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.jconrel.2015.05.003_bb0045","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1124\/mol.112.079129","article-title":"Drug efflux transporters and multidrug resistance in acute leukemia: therapeutic impact and novel approaches to mediation","volume":"82","author":"Xia","year":"2012","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2013.04.025","article-title":"Functional alginate nanoparticles for efficient intracellular release of doxorubicin and hepatoma carcinoma cell targeting therapy","volume":"451","author":"Guo","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0055","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1158\/1535-7163.MCT-06-0141","article-title":"Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery","volume":"5","author":"Sinha","year":"2006","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0060","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1016\/j.addr.2013.09.017","article-title":"Nanotechnology approaches for personalized treatment of multidrug resistant cancers","volume":"65","author":"Minko","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0065","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.2174\/18715206113136660350","article-title":"Colorectal cancer in elderly patients: from best supportive care to cure","volume":"13","author":"Berretta","year":"2013","journal-title":"Anti Cancer Agents Med. Chem."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0070","first-page":"706","article-title":"Prevalence and treatment of oncologic disease in the elderly \u2014 an impeding challenge","volume":"100","author":"G\u00f3mez Portilla","year":"2008","journal-title":"Rev. Esp. Enferm. Dig."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0075","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.molmed.2015.01.001","article-title":"Cancer nanomedicine: from targeted delivery to combination therapy","volume":"21","author":"Xu","year":"2015","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0080","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.drudis.2012.03.010","article-title":"Theranostic applications of nanoparticles in cancer","volume":"17","author":"Ahmed","year":"2012","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jconrel.2015.05.003_bb0085","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/sj.clpt.6100400","article-title":"Nanoparticles in medicine: therapeutic applications and developments","volume":"83","author":"Zhang","year":"2007","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0090","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/j.addr.2008.08.005","article-title":"Active targeting schemes for nanoparticle systems in cancer therapeutics","volume":"60","author":"Byrne","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0095","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/B978-0-12-391860-4.00006-9","article-title":"Multistage nanoparticles for improved delivery into tumor tissue","volume":"508","author":"Stylianopoulos","year":"2012","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0100","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0163-7827(03)00032-8","article-title":"Ligand-targeted liposomal anticancer drugs","volume":"42","author":"Sapra","year":"2003","journal-title":"Prog. Lipid Res."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0105","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.drudis.2006.07.005","article-title":"Exploiting the enhanced permeability and retention effect for tumor targeting","volume":"11","author":"Iyer","year":"2006","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jconrel.2015.05.003_bb0110","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/nrc903","article-title":"Ligand-targeted therapeutics in anticancer therapy","volume":"2","author":"Allen","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2015.05.003_bb0115","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1093\/jnci\/djh221","article-title":"Immune cell-mediated antitumor activities of GD2-targeted liposomal c-myb antisense oligonucleotides containing CpG motifs","volume":"96","author":"Brignole","year":"2004","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0120","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jconrel.2012.01.043","article-title":"PLGA-based nanoparticles: an overview of biomedical applications","volume":"161","author":"Danhier","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2015.05.003_bb0125","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1097\/00001813-199909000-00010","article-title":"Dendrimer-platinate: a novel approach to cancer chemotherapy","volume":"10","author":"Malik","year":"1999","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.jconrel.2015.05.003_bb0130","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1021\/mp300213g","article-title":"Transferrin-conjugated micelles: enhanced accumulation and antitumor effect for transferrin-receptor-overexpressing cancer models","volume":"9","author":"Yue","year":"2012","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0135","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1021\/nn800551s","article-title":"Targeted killing of cancer cells in vivo and in vitro with EGF-directed carbon nanotube-based drug delivery","volume":"3","author":"Bhirde","year":"2009","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2015.05.003_bb0140","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.taap.2014.01.012","article-title":"Ligand-conjugated mesoporous silica nanorattles based on enzyme targeted prodrug delivery system for effective lung cancer therapy","volume":"275","author":"Sundarraj","year":"2014","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0145","article-title":"Monoclonal antibody conjugated magnetic nanoparticles could target MUC-1-positive cells in vitro but not in vivo","author":"Shanehsazzadeh","year":"2014","journal-title":"Contrast Media Mol. Imaging"},{"key":"10.1016\/j.jconrel.2015.05.003_bb0150","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0092-8674(02)00621-9","article-title":"Cancer modeling in the modern era","volume":"108","author":"Van Dyke","year":"2002","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2015.05.003_bb0155","first-page":"622","article-title":"The National Cancer Institute: cancer drug discovery and development program","volume":"19","author":"Grever","year":"1992","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0160","doi-asserted-by":"crossref","first-page":"20120939","DOI":"10.1098\/rsif.2012.0939","article-title":"New views on cellular uptake and trafficking of manufactured nanoparticles","volume":"10","author":"Treuel","year":"2013","journal-title":"J. R. Soc. Interface"},{"key":"10.1016\/j.jconrel.2015.05.003_bb0165","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.jconrel.2013.09.026","article-title":"Mind the gap: a survey of how cancer drug carriers are susceptible to the gap between research and practice","volume":"172","author":"Stirland","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2015.05.003_bb0170","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.2174\/092986712800784702","article-title":"Drug-loaded nanocarriers: passive targeting and crossing of biological barriers","volume":"19","author":"Rabanel","year":"2012","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0175","doi-asserted-by":"crossref","first-page":"e29528","DOI":"10.4161\/tisb.29528","article-title":"Barriers to drug delivery in solid tumors","volume":"2","author":"Sriraman","year":"2014","journal-title":"Tissue Barriers"},{"key":"10.1016\/j.jconrel.2015.05.003_bb0180","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S1359-6446(03)02988-X","article-title":"Active targeting with particulate drug carriers in tumor therapy: fundamentals and recent progress","volume":"9","author":"Marcucci","year":"2004","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jconrel.2015.05.003_bb0185","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0014-5793(02)02821-1","article-title":"Anti-neovascular therapy by liposomal DPP-CNDAC targeted to angiogenic vessels","volume":"520","author":"Asai","year":"2002","journal-title":"FEBS Lett."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0190","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jconrel.2011.09.063","article-title":"Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress","volume":"161","author":"Lammers","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2015.05.003_bb0195","first-page":"1","article-title":"Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology","author":"Bertrand","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0200","first-page":"6942","article-title":"Antibody targeting of doxorubicin-loaded liposomes suppresses the growth and metastatic spread of established human lung tumor xenografts in severe combined immunodeficient mice","volume":"60","author":"Sugano","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0205","doi-asserted-by":"crossref","first-page":"8858","DOI":"10.1016\/j.biomaterials.2012.08.043","article-title":"Tumor cells-specific targeting delivery achieved by A54 peptide functionalized polymeric micelles","volume":"33","author":"Du","year":"2012","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2015.05.003_bb0210","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1007\/s10439-011-0333-2","article-title":"Intracellular delivery of mitomycin C with targeted polysaccharide conjugates against multidrug resistance","volume":"39","author":"Cao","year":"2011","journal-title":"Ann. Biomed. Eng."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0215","doi-asserted-by":"crossref","first-page":"7668","DOI":"10.1158\/0008-5472.CAN-04-2550","article-title":"Nanoparticle\u2013aptamer bioconjugates: a new approach for targeting prostate cancer cells","author":"Farokhzad","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0220","doi-asserted-by":"crossref","first-page":"528123","DOI":"10.1155\/2012\/528123","article-title":"Nanoparticles for targeted delivery of active agents against tumor cells","volume":"2012","author":"Dinarvand","year":"2012","journal-title":"J. Drug Deliv."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0225","first-page":"1172","article-title":"Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery","volume":"8","author":"Park","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0230","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1093\/jnci\/85.15.1230","article-title":"Stability of HER-2\/neu expression over time and at multiple metastatic sites","volume":"85","author":"Niehans","year":"1993","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0235","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.2217\/nnm.12.87","article-title":"Nanotechnology in therapeutics: a focus on nanoparticles as a drug delivery system","volume":"7","author":"Bamrungsap","year":"2012","journal-title":"Nanomedicine (London)"},{"key":"10.1016\/j.jconrel.2015.05.003_bb0240","doi-asserted-by":"crossref","first-page":"5317","DOI":"10.1158\/0008-5472.CAN-04-3921","article-title":"Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer","volume":"65","author":"Kukowska-Latallo","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0245","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/ijc.20405","article-title":"Efficacy of transferrin-conjugated paclitaxel-loaded nanoparticles in a murine model of prostate cancer","volume":"112","author":"Sahoo","year":"2004","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.jconrel.2015.05.003_bb0250","doi-asserted-by":"crossref","first-page":"e1000100","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"Liberati","year":"2009","journal-title":"PLoS Med."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0255","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.ijbiomac.2009.11.008","article-title":"Self-assembled nanoparticle drug delivery systems from galactosylated polysaccharide\u2013doxorubicin conjugate loaded doxorubicin","volume":"46","author":"Cao","year":"2010","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0260","doi-asserted-by":"crossref","first-page":"7594","DOI":"10.1016\/j.biomaterials.2012.06.072","article-title":"Glycyrrhizin-modified O-carboxymethyl chitosan nanoparticles as drug vehicles targeting hepatocellular carcinoma","volume":"33","author":"Shi","year":"2012","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2015.05.003_bb0265","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.4161\/cbt.22001","article-title":"Preliminary pharmacology of galactosylated chitosan\/5-fluorouracil nanoparticles and its inhibition of hepatocellular carcinoma in mice","volume":"13","author":"Cheng","year":"2012","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0270","doi-asserted-by":"crossref","first-page":"e831","DOI":"10.1038\/cddis.2013.347","article-title":"Epithelial\u2013mesenchymal transition markers expressed in circulating tumor cells in hepatocellular carcinoma patients with different stages of disease","volume":"4","author":"Li","year":"2013","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0275","doi-asserted-by":"crossref","first-page":"3783","DOI":"10.1158\/1078-0432.CCR-10-0498","article-title":"Isolation of circulating tumor cells in patients with hepatocellular carcinoma using a novel cell separation strategy","volume":"17","author":"Xu","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0280","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1200\/JCO.2002.20.6.1668","article-title":"Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin","volume":"20","author":"Seymour","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0285","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3109\/10611869608996829","article-title":"Gamma scintigraphy of a 1231-labelled N-(2-hydroxypropyl) methacrylamide copolymer-doxorubicin conjugate containing galactosamine following intravenous administration to nude mice bearing hepatic human colon carcinoma","volume":"3","author":"Pimm","year":"1996","journal-title":"J. Drug Target."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0290","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/sj.bjc.6690708","article-title":"The asialoglycoprotein receptor in human hepatocellular carcinomas: its expression on proliferating cells","volume":"81","author":"Trer\u00e8","year":"1999","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jconrel.2015.05.003_bb0295","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1126\/science.1095833","article-title":"Drug delivery systems: entering the mainstream","volume":"303","author":"Allen","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2015.05.003_bb0300","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.addr.2012.06.012","article-title":"Tumor-targeting multi-functional nanoparticles for theragnosis: new paradigm for cancer therapy","volume":"64","author":"Ryu","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0305","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1248\/cpb.59.63","article-title":"Drug pH-sensitive release in vitro and targeting ability of polyamidoamine dendrimer complexes for tumor cells","volume":"59","author":"Iu","year":"2011","journal-title":"Chem. Pharm. Bull."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0310","first-page":"5465","article-title":"Lactosylated liposomes for targeted delivery of doxorubicin to hepatocellular carcinoma","volume":"7","author":"Zhou","year":"2012","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2015.05.003_bb0315","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1002\/jbm.b.32767","article-title":"Synthesis of galactosylated chitosan\/5-fluorouracil nanoparticles and its characteristics, in vitro and in vivo release studies","volume":"100","author":"Cheng","year":"2012","journal-title":"J. Biomed. Mater. Res. B Appl. Biomater."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0320","doi-asserted-by":"crossref","first-page":"9246","DOI":"10.1016\/j.biomaterials.2012.09.027","article-title":"Dual-functional liposomes based on pH-responsive cell-penetrating peptide and hyaluronic acid for tumor-targeted anticancer drug delivery","volume":"33","author":"Jiang","year":"2012","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2015.05.003_bb0325","doi-asserted-by":"crossref","first-page":"6076","DOI":"10.3748\/wjg.v18.i42.6076","article-title":"Galactosylated chitosan\/5-fluorouracil nanoparticles inhibit mouse hepatic cancer growth and its side effects","volume":"18","author":"Cheng","year":"2012","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0330","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s11095-011-0603-6","article-title":"Liver cancer targeting of Doxorubicin with reduced distribution to the heart using hematoporphyrin-modified albumin nanoparticles in rats","volume":"29","author":"Chang","year":"2012","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0335","first-page":"107","article-title":"Utility of liposomes coated with polysaccharide bearing 1-amino-lactose as targeting chemotherapy for AH66 hepatoma cells","volume":"7","author":"Yamamoto","year":"2000","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0340","doi-asserted-by":"crossref","first-page":"e47115","DOI":"10.1371\/journal.pone.0047115","article-title":"5-Fluorouracil nanoparticles inhibit hepatocellular carcinoma via activation of the p53 pathway in the orthotopic transplant mouse model","volume":"7","author":"Cheng","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2015.05.003_bb0345","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/0304-4165(86)90120-0","article-title":"Fate of N-(2-hydroxypropyl)methacrylamide copolymers with pendent galactosamine residues after intravenous administration to rats","volume":"880","author":"Duncan","year":"1986","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.jconrel.2015.05.003_bb0350","first-page":"5718","article-title":"Isolation of preneoplastic rat liver cells by centrifugal elutriation and binding to asialofetuin","volume":"44","author":"Evarts","year":"1984","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0355","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/9780470122860.ch3","article-title":"The role of surface carbohydrates in the hepatic recognition and transport of circulating glycoproteins","volume":"41","author":"Ashwell","year":"1974","journal-title":"Adv. Enzymol. Relat. Areas Mol. Biol."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0360","first-page":"83","article-title":"Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I\/II Committee","volume":"5","author":"Vasey","year":"1999","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0365","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jconrel.2009.08.011","article-title":"Targeting of tumor endothelium by RGD-grafted PLGA-nanoparticles loaded with paclitaxel","volume":"140","author":"Danhier","year":"2009","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2015.05.003_bb0370","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ijpharm.2010.03.018","article-title":"Active and passive tumor targeting of a novel poorly soluble cyclin dependent kinase inhibitor, JNJ-7706621","volume":"392","author":"Danhier","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0375","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s10856-008-3577-0","article-title":"Preparation and properties of a novel drug delivery system with both magnetic and biomolecular targeting","volume":"20","author":"Yang","year":"2009","journal-title":"J. Mater. Sci. Mater. Med."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0380","first-page":"6387","article-title":"Peptide-conjugated PAMAM for targeted doxorubicin delivery to transferrin receptor overexpressed tumors","volume":"46","author":"Han","year":"2010","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0385","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1046\/j.1432-1327.2001.02073.x","article-title":"Receptor mediated uptake of peptides that bind the human transferrin receptor","volume":"268","author":"Lee","year":"2001","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0390","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.canlet.2008.08.031","article-title":"Synthesis and anti-cancer activity of covalent conjugates of artemisinin and a transferrin-receptor targeting peptide","volume":"274","author":"Oh","year":"2009","journal-title":"Cancer Lett."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0395","first-page":"426","article-title":"Immunohistochemical demonstration of transferrin receptor 1 and 2 in human hepatocellular carcinoma tissue","volume":"61","author":"Sakurai","year":"2014","journal-title":"Hepatogastroenterology"},{"key":"10.1016\/j.jconrel.2015.05.003_bb0400","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1365-2559.1988.tb01916.x","article-title":"Transferrin receptor expression in human hepatocellular carcinoma: an immunohistochemical study of 34 cases","volume":"12","author":"SCIOT","year":"1988","journal-title":"Histopathology"},{"key":"10.1016\/j.jconrel.2015.05.003_bb0405","doi-asserted-by":"crossref","first-page":"C1567","DOI":"10.1152\/ajpcell.00649.2008","article-title":"The role of transferrin receptor 1 and 2 in transferrin-bound iron uptake in human hepatoma cells","volume":"297","author":"Herbison","year":"2009","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0410","doi-asserted-by":"crossref","first-page":"3782","DOI":"10.1182\/blood-2002-01-0076","article-title":"Structural, functional, and tissue distribution analysis of human transferrin receptor-2 by murine monoclonal antibodies and a polyclonal antiserum","volume":"100","author":"Deaglio","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2015.05.003_bb0415","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1097\/PAS.0b013e31821247a8","article-title":"CD71 is selectively and ubiquitously expressed at high levels in erythroid precursors of all maturation stages: a comparative immunochemical study with glycophorin A and hemoglobin A","volume":"35","author":"Dong","year":"2011","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0420","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1158\/1541-7786.MCR-09-0339","article-title":"Targeted drug delivery to hepatocarcinoma in vivo by phage-displayed specific binding peptide","volume":"8","author":"Du","year":"2010","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0425","doi-asserted-by":"crossref","first-page":"9343","DOI":"10.1073\/pnas.0803728105","article-title":"Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis","volume":"105","author":"Murphy","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0430","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1039\/B517706E","article-title":"Multivalent RGD synthetic peptides as potent alphaVbeta3 integrin ligands","volume":"4","author":"Garanger","year":"2006","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0435","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1126\/science.7512751","article-title":"Requirement of vascular integrin alpha v beta 3 for angiogenesis","volume":"264","author":"Brooks","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2015.05.003_bb0440","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nrc2748","article-title":"Integrins in cancer: biological implications and therapeutic opportunities","volume":"10","author":"Desgrosellier","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2015.05.003_bb0445","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1038\/nm0902-918","article-title":"A reevaluation of integrins as regulators of angiogenesis","volume":"8","author":"Hynes","year":"2002","journal-title":"Nat. Med."},{"issue":"80-","key":"10.1016\/j.jconrel.2015.05.003_bb0450","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1126\/science.279.5349.377","article-title":"Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model","volume":"279","author":"Arap","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2015.05.003_bb0455","doi-asserted-by":"crossref","first-page":"367","DOI":"10.3109\/1061186X.2012.757769","article-title":"Delivery of hydrophilic drug doxorubicin hydrochloride-targeted liver using apoAI as carrier","volume":"21","author":"Yuan","year":"2013","journal-title":"J. Drug Target."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0460","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.1016\/j.biomaterials.2012.03.067","article-title":"CD44 antibody-targeted liposomal nanoparticles for molecular imaging and therapy of hepatocellular carcinoma","volume":"33","author":"Wang","year":"2012","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2015.05.003_bb0465","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1080\/10611860701502723","article-title":"Effects on hepatocellular carcinoma of doxorubicin-loaded immunoliposomes designed to target the VEGFR-2","volume":"15","author":"Roth","year":"2007","journal-title":"J. Drug Target."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0470","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1021\/bm1005992","article-title":"Improved therapeutic effect of DOX\u2013PLGA\u2013PEG micelles decorated with bivalent fragment HAb18 F(ab\u2032)(2) for hepatocellular carcinoma","volume":"11","author":"Jin","year":"2010","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.jconrel.2015.05.003_bb0475","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.yexmp.2010.05.005","article-title":"Immunohistochemical staining of cancer stem cell markers in hepatocellular carcinoma","volume":"89","author":"Lingala","year":"2010","journal-title":"Exp. Mol. Pathol."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0480","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1186\/1471-2407-14-722","article-title":"Cancer stem-like sphere cells induced from de-differentiated hepatocellular carcinoma-derived cell lines possess the resistance to anti-cancer drugs","volume":"14","author":"Hashimoto","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jconrel.2015.05.003_bb0485","doi-asserted-by":"crossref","first-page":"E161","DOI":"10.1002\/ijc.29097","article-title":"A mesenchymal-like phenotype and expression of CD44 predict lack of apoptotic response to sorafenib in liver tumor cells","volume":"136","author":"Fernando","year":"2015","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.jconrel.2015.05.003_bb0490","first-page":"6624","article-title":"Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2","volume":"61","author":"Kunkel","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0495","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1111\/j.0906-6705.2004.00240.x","article-title":"Anti-vascular endothelial growth factor receptor-2 (Flk-1\/KDR) antibody suppresses contact hypersensitivity","volume":"13","author":"Watanabe","year":"2004","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0500","first-page":"1489","article-title":"Therapeutic efficiency of folated poly(ethylene glycol)-chitosan-graft-polyethylenimine-Pdcd4 complexes in H-ras12V mice with liver cancer","volume":"8","author":"Kim","year":"2013","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2015.05.003_bb0505","doi-asserted-by":"crossref","first-page":"4995","DOI":"10.1016\/j.biomaterials.2010.02.068","article-title":"Multifunctional doxorubicin loaded superparamagnetic iron oxide nanoparticles for chemotherapy and magnetic resonance imaging in liver cancer","volume":"31","author":"Maeng","year":"2010","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2015.05.003_bb0510","first-page":"4043","article-title":"Glycyrrhetinic acid and related compounds induce G1 arrest and apoptosis in human hepatocellular carcinoma HepG2","volume":"25","author":"Satomi","year":"2005","journal-title":"Anticancer Res."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0515","first-page":"215","article-title":"Glycyrrhetic acid (a metabolic substance and aglycon of glycyrrhizin) induces apoptosis in human hepatoma, promyelotic leukemia and stomach cancer cells","volume":"17","author":"Hibasami","year":"2006","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0520","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.nano.2011.11.002","article-title":"Self-assembly and liver targeting of sulfated chitosan nanoparticles functionalized with glycyrrhetinic acid","volume":"8","author":"Tian","year":"2012","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2015.05.003_bb0525","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s10856-011-4262-2","article-title":"Glycyrrhetinic acid-functionalized degradable micelles as liver-targeted drug carrier","volume":"22","author":"Huang","year":"2011","journal-title":"J. Mater. Sci. Mater. Med."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0530","doi-asserted-by":"crossref","first-page":"4748","DOI":"10.1016\/j.biomaterials.2010.02.042","article-title":"Glycyrrhetinic acid-modified chitosan\/poly(ethylene glycol) nanoparticles for liver-targeted delivery","volume":"31","author":"Tian","year":"2010","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2015.05.003_bb0535","doi-asserted-by":"crossref","first-page":"467","DOI":"10.3109\/1061186X.2012.685475","article-title":"The anti-tumor performance of docetaxel liposomes surface-modified with glycyrrhetinic acid","volume":"20","author":"Li","year":"2012","journal-title":"J. Drug Target."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0540","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/0005-2736(91)90253-5","article-title":"Specific binding of glycyrrhetinic acid to the rat liver membrane","volume":"1066","author":"Negishi","year":"1991","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.jconrel.2015.05.003_bb0545","article-title":"Safety of nanoparticles in medicine","author":"Wolfram","year":"2014","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.jconrel.2015.05.003_bb0550","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1080\/026520400417676","article-title":"5-Fluorouracil-loaded chitosan coated polylactic acid microspheres as biodegradable drug carriers for cerebral tumours","volume":"17","author":"Chandy","year":"2000","journal-title":"J. Microencapsul."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0555","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.colsurfb.2008.07.020","article-title":"Chitosan-coated magnetic nanoparticles as carriers of 5-fluorouracil: preparation, characterization and cytotoxicity studies","volume":"68","author":"Zhu","year":"2009","journal-title":"Colloids Surf. B: Biointerfaces"},{"key":"10.1016\/j.jconrel.2015.05.003_bb0560","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1163\/156856202320813846","article-title":"Synthesis and biological properties of antitumor-active conjugates of ADR with dextran","volume":"13","author":"Guu","year":"2002","journal-title":"J. Biomater. Sci. Polym. Ed."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0565","doi-asserted-by":"crossref","first-page":"12905","DOI":"10.1074\/jbc.M900280200","article-title":"Antiangiogenic targeting liposomes increase therapeutic efficacy for solid tumors","volume":"284","author":"Chang","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0570","doi-asserted-by":"crossref","first-page":"10820","DOI":"10.1073\/pnas.95.18.10820","article-title":"Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor","volume":"95","author":"Jain","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0575","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0168-3659(03)00240-2","article-title":"Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin","volume":"91","author":"Schiffelers","year":"2003","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2015.05.003_bb0580","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1158\/1078-0432.CCR-11-1102","article-title":"Targeting tumor-associated endothelial cells: anti-VEGFR2 immunoliposomes mediate tumor vessel disruption and inhibit tumor growth","volume":"18","author":"Wicki","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0585","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ijpharm.2005.02.030","article-title":"Applicability of anti-neovascular therapy to drug-resistant tumor: suppression of drug-resistant P388 tumor growth with neovessel-targeted liposomal adriamycin","volume":"296","author":"Shimizu","year":"2005","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0590","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1038\/sj.onc.1205347","article-title":"Anti-neovascular therapy using novel peptides homing to angiogenic vessels","volume":"21","author":"Oku","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.jconrel.2015.05.003_bb0595","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1111\/j.1349-7006.2008.00758.x","article-title":"Antineovascular therapy with angiogenic vessel-targeted polyethyleneglycol-shielded liposomal DPP-CNDAC","volume":"99","author":"Asai","year":"2008","journal-title":"Cancer Sci."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0600","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jconrel.2004.07.033","article-title":"Anti-neovascular therapy by use of tumor neovasculature-targeted long-circulating liposome","volume":"100","author":"Maeda","year":"2004","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2015.05.003_bb0605","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1021\/jm00113a034","article-title":"Nucleosides and nucleotides. 100. 2\u2032-C-cyano-2\u2032-deoxy-1-beta-D-arabinofuranosyl-cytosine (CNDAC): design of a potential mechanism-based DNA-strand-breaking antineoplastic nucleoside","volume":"34","author":"Matsuda","year":"1991","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0610","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/0014-5793(90)81016-H","article-title":"Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes","volume":"268","author":"Klibanov","year":"1990","journal-title":"FEBS Lett."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0615","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0169-409X(02)00226-0","article-title":"PEGylated nanoparticles for biological and pharmaceutical applications","volume":"55","author":"Otsuka","year":"2003","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0620","doi-asserted-by":"crossref","first-page":"6163","DOI":"10.1016\/j.biomaterials.2013.04.062","article-title":"Nanoparticle-mediated drug delivery to tumor neovasculature to combat P-gp expressing multidrug resistant cancer","volume":"34","author":"Bai","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2015.05.003_bb0625","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ejps.2010.05.012","article-title":"Novel steroid carbamates reverse multidrug-resistance in cancer therapy and show linkage among efficacy, loci of drug action and P-glycoprotein's cellular localization","volume":"41","author":"Argov","year":"2010","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0630","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jconrel.2006.03.001","article-title":"In-vivo efficacy of novel paclitaxel nanoparticles in paclitaxel-resistant human colorectal tumors","volume":"112","author":"Koziara","year":"2006","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2015.05.003_bb0635","doi-asserted-by":"crossref","first-page":"43137","DOI":"10.1074\/jbc.M203103200","article-title":"A novel peptide isolated from a phage display library inhibits tumor growth and metastasis by blocking the binding of vascular endothelial growth factor to its kinase domain receptor","volume":"277","author":"Hetian","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0640","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/cam4.105","article-title":"Vessel co-option in primary human tumors and metastases: an obstacle to effective anti-angiogenic treatment?","volume":"2","author":"Donnem","year":"2013","journal-title":"Cancer Med."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0645","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/nrc704","article-title":"Hypoxia\u2014a key regulatory factor in tumour growth","volume":"2","author":"Harris","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2015.05.003_bb0650","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/nrc2344","article-title":"Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability","volume":"8","author":"Bristow","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2015.05.003_bb0655","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/nrc3726","article-title":"Hypoxia and the extracellular matrix: drivers of tumour metastasis","volume":"14","author":"Gilkes","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2015.05.003_bb0660","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.taap.2013.03.028","article-title":"Hypoxia inducible factor-1 (HIF-1)\u2013flavin containing monooxygenase-2 (FMO-2) signaling acts in silver nanoparticles and silver ion toxicity in the nematode, Caenorhabditis","volume":"270","author":"Eom","year":"2013","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0665","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1021\/mp300193f","article-title":"Therapeutic delivery of siRNA silencing HIF-1 alpha with micellar nanoparticles inhibits hypoxic tumor growth","volume":"9","author":"Liu","year":"2012","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0670","first-page":"5799","article-title":"CAR-3, a monoclonal antibody-defined antigen expressed on human carcinomas","volume":"45","author":"Prat","year":"1985","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0675","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/0277-5379(87)90337-3","article-title":"Expression of the monoclonal antibody-defined CAR-3 epitope on neoplastic and preneoplastic lesions of the colon mucosa","volume":"23","author":"Prat","year":"1987","journal-title":"Eur. J. Cancer Clin. Oncol."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0680","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1021\/js9604467","article-title":"Antitumoral activity of liposomes and immunoliposomes containing 5-fluorouridine prodrugs","volume":"86","author":"Crosasso","year":"1997","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0685","first-page":"1415","article-title":"Biochemical and immunological properties of the human carcinoma-associated CAR-3 epitope defined by the monoclonal antibody AR-3","volume":"49","author":"Prat","year":"1989","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0690","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1038\/sj.bjc.6601341","article-title":"Efficacy of immunoliposomes on cancer models in a cell-surface-antigen-density-dependent manner","volume":"89","author":"Hosokawa","year":"2003","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jconrel.2015.05.003_bb0695","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1093\/annonc\/mdm007","article-title":"Autoantibodies in breast cancer: their use as an aid to early diagnosis","volume":"18","author":"Chapman","year":"2007","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0700","first-page":"258","article-title":"Humoral immune responses to XMMCO-791-RTA immunotoxin in colorectal cancer patients","volume":"75","author":"Durrant","year":"1989","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0705","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1111\/j.1349-7006.2004.tb02495.x","article-title":"Antitumor effect of MCC-465, pegylated liposomal doxorubicin tagged with newly developed monoclonal antibody GAH, in colorectal cancer xenografts","volume":"95","author":"Hamaguchi","year":"2004","journal-title":"Cancer Sci."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0710","first-page":"4282","article-title":"Novel Chondroitin Sulfate-binding Cationic Liposomes Loaded with Cisplatin Efficiently Suppress the Local Growth and Liver Metastasis of Tumor Cells in Vivo","volume":"62","author":"Lee","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0715","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ejps.2013.06.015","article-title":"Epirubicin loaded super paramagnetic iron oxide nanoparticle-aptamer bioconjugate for combined colon cancer therapy and imaging in vivo","volume":"50","author":"Jalalian","year":"2013","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0720","first-page":"1","article-title":"Cell-specific aptamers and their conjugation with nanomaterials for targeted drug delivery","author":"Liao","year":"2014","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0725","doi-asserted-by":"crossref","first-page":"234","DOI":"10.5483\/BMBRep.2015.48.4.277","article-title":"Therapeutic aptamers: Developmental potential as anticancer drugs","volume":"48","author":"Lee","year":"2015","journal-title":"BMB Rep."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0730","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1136\/jcp.2009.071035","article-title":"Alterations in glycosylation as biomarkers for cancer detection","volume":"63","author":"Reis","year":"2010","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0735","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.canlet.2006.08.010","article-title":"Biological significance of cancer-associated sialyl-Tn antigen: modulation of malignant phenotype in gastric carcinoma cells","volume":"249","author":"Pinho","year":"2007","journal-title":"Cancer Lett."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0740","doi-asserted-by":"crossref","first-page":"9101","DOI":"10.1007\/s13277-014-2186-4","article-title":"Quantitative assessment of the diagnostic role of MUC1 in pancreatic ductal adenocarcinoma","volume":"35","author":"Wang","year":"2014","journal-title":"Tumour Biol."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0745","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/ijc.26354","article-title":"Differential glycosylation of MUC1 and CEACAM5 between normal mucosa and tumour tissue of colon cancer patients","volume":"131","author":"Saeland","year":"2012","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.jconrel.2015.05.003_bb0750","doi-asserted-by":"crossref","first-page":"e49251","DOI":"10.1371\/journal.pone.0049251","article-title":"MUC4 and MUC1 expression in adenocarcinoma of the stomach correlates with vessel invasion and lymph node metastasis: an immunohistochemical study of early gastric cancer","volume":"7","author":"Tamura","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2015.05.003_bb0755","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1093\/glycob\/cwj044","article-title":"Chemoenzymatically synthesized multimeric Tn\/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance","volume":"16","author":"S\u00f8rensen","year":"2006","journal-title":"Glycobiology"},{"key":"10.1016\/j.jconrel.2015.05.003_bb0760","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/ijc.10242","article-title":"Intracellular targeting therapy of cisplatin-encapsulated transferrin-polyethylene glycol liposome on peritoneal dissemination of gastric cancer","volume":"137","author":"Inuma","year":"2002","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.jconrel.2015.05.003_bb0765","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1023\/A:1010960900254","article-title":"Liposomes Bearing Polyethyleneglycol-Coupled Transferrin with Intracellular Targeting Property to the Solid Tumors In Vivo","volume":"18","author":"Ishida","year":"2001","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0770","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1245\/s10434-011-1739-7","article-title":"Absence of CD71 transferrin receptor characterizes human gastric adenosquamous carcinoma stem cells","volume":"19","author":"Ohkuma","year":"2012","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0775","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/cgt.2013.9","article-title":"Transferrin receptor targeting nanomedicine delivering wild-type p53 gene sensitizes pancreatic cancer to gemcitabine therapy","volume":"20","author":"Camp","year":"2013","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0780","article-title":"Targeted delivery of siRNA using transferrin-coupled lipoplexes specifically sensitizes CD71 high expressing malignant cells to antibody-mediated complement attack","author":"Cinci","year":"2014","journal-title":"Target. Oncol."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0785","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s00232-014-9637-0","article-title":"Transferrin receptor-mediated endocytosis: a useful target for cancer therapy","volume":"247","author":"Tortorella","year":"2014","journal-title":"J. Membr. Biol."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0790","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1111\/j.1349-7006.2006.00291.x","article-title":"Identification of oligopeptides binding to peritoneal tumors of gastric cancer","volume":"97","author":"Akita","year":"2006","journal-title":"Cancer Sci."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0795","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1271\/bbb.80096","article-title":"Evaluation of multi-target and single-target liposomal drugs for the treatment of gastric cancer","volume":"72","author":"Chen","year":"2014","journal-title":"Biosci. Biotechnol. Biochem."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0800","article-title":"Towards oral delivery of biopharmaceuticals: an assessment of the gastrointestinal stability of 17 peptide drugs","author":"Basit","year":"2015","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0805","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1016\/j.acthis.2014.09.005","article-title":"Identification and localization of gastrointestinal hormones in the skin of the bullfrog Rana catesbeiana during periods of activity and hibernation","volume":"116","author":"Wang","year":"2014","journal-title":"Acta Histochem."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0810","doi-asserted-by":"crossref","first-page":"e223","DOI":"10.1111\/j.1365-2982.2011.01706.x","article-title":"Central somatostatin receptor 1 activation reverses acute stress-related alterations of gastric and colonic motor function in mice","volume":"23","author":"Stengel","year":"2011","journal-title":"Neurogastroenterol. Motil."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0815","article-title":"Somatostatin and its Analogs","author":"Sun","year":"2014","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.jconrel.2015.05.003_bb0820","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1517\/13543784.2014.942728","article-title":"Investigational drugs targeting somatostatin receptors for treatment of acromegaly and neuroendocrine tumors","volume":"23","author":"Giustina","year":"2014","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.jconrel.2015.05.003_bb0825","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1002\/med.20238","article-title":"Targeted drug delivery and penetration into solid tumors","volume":"32","author":"Corti","year":"2012","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0830","doi-asserted-by":"crossref","first-page":"726","DOI":"10.4161\/cbt.3.8.962","article-title":"The effect of somatostatin and SSTR3 on proliferation and apoptosis of gastric cancer cells","volume":"3","author":"Hu","year":"2014","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0835","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1039\/c0np00035c","article-title":"Biosynthesis, total syntheses, and antitumor activity of tanshinones and their analogs as potential therapeutic agents","volume":"28","author":"Dong","year":"2011","journal-title":"Nat. Prod. Rep."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0840","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.lfs.2013.07.007","article-title":"Dihydrotanshinone induces p53-independent but ROS-dependent apoptosis in colon cancer cells","volume":"93","author":"Wang","year":"2013","journal-title":"Life Sci."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0845","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1271\/bbb.63.1370","article-title":"Inhibition of DNA topoisomerase I by dihydrotanshinone I, components of a medicinal herb Salvia miltiorrhiza Bunge","volume":"63","author":"Lee","year":"2014","journal-title":"Biosci. Biotechnol. Biochem."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0850","first-page":"51","article-title":"Inhibitory and cytotoxic activities of salvia officinalis L. Extract on human lymphoma and leukemia cells by induction of apoptosis","volume":"3","author":"Zare Shahneh","year":"2013","journal-title":"Adv. Pharm. Bull."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0855","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1038\/bjc.1996.625","article-title":"Targeting of stealth liposomes to erbB-2 (Her\/2) receptor: in vitro and in vivo studies","volume":"74","author":"Goren","year":"1996","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jconrel.2015.05.003_bb0860","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/j.1349-7006.1994.tb02377.x","article-title":"Therapeutic effect by using Fab\u2032 fragment in the treatment of carcinoembryonic antigen\u2010positive human solid tumors with adriamycinentrapped immunoliposomes","volume":"85","author":"Uyama","year":"1994","journal-title":"Jpn. J. Cancer Res"},{"key":"10.1016\/j.jconrel.2015.05.003_bb0865","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1186\/1477-7819-12-397","article-title":"Clinical evaluation of CEA, CA19-9, CA72-4 and CA125 in gastric cancer patients with neoadjuvant chemotherapy","volume":"12","author":"Sun","year":"2014","journal-title":"World J. Surg. Oncol."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0870","doi-asserted-by":"crossref","first-page":"221","DOI":"10.5230\/jgc.2014.14.4.221","article-title":"The value of postoperative serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for the early detection of gastric cancer recurrence after curative resection","volume":"14","author":"Lee","year":"2014","journal-title":"J. Gastric Cancer"},{"key":"10.1016\/j.jconrel.2015.05.003_bb0875","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1158\/1078-0432.CCR-03-0041","article-title":"Improved therapeutic responses in a xenograft model of human B lymphoma (Namalwa) for liposomal vincristine versus liposomal doxorubicin targeted via anti-CD19 IgG2a or Fab\u2032 fragments","volume":"10","author":"Sapra","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0880","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1093\/annonc\/mdh092","article-title":"Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer","volume":"15","author":"Matsumura","year":"2004","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0885","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1136\/gutjnl-2012-303588","article-title":"Current concepts and novel targets in advanced pancreatic cancer","volume":"62","author":"Michl","year":"2013","journal-title":"Gut"},{"key":"10.1016\/j.jconrel.2015.05.003_bb0890","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.gassur.2006.08.018","article-title":"1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience","volume":"10","author":"Winter","year":"2006","journal-title":"J. Gastrointest. Surg."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0895","series-title":"Cancer Facts & Figures","first-page":"25","author":"Amican Cancer Society","year":"2012"},{"key":"10.1016\/j.jconrel.2015.05.003_bb0900","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1126\/science.1171362","article-title":"Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer","volume":"324","author":"Olive","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2015.05.003_bb0905","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1158\/1535-7163.MCT-10-0729","article-title":"Targeted nanogels: a versatile platform for drug delivery to tumors","volume":"10","author":"Murphy","year":"2011","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.jconrel.2015.05.003_bb0910","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.bbagen.2011.07.016","article-title":"The transferrin receptor and the targeted delivery of therapeutic agents against cancer","volume":"1820","author":"Daniels","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.jconrel.2015.05.003_bb0915","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.clim.2006.06.006","article-title":"The transferrin receptor part II: targeted delivery of therapeutic agents into cancer cells","volume":"121","author":"Daniels","year":"2006","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0920","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.clim.2006.06.010","article-title":"The transferrin receptor part I: biology and targeting with cytotoxic antibodies for the treatment of cancer","volume":"121","author":"Daniels","year":"2006","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0925","first-page":"337","article-title":"Systemic tumor-targeted gene delivery by anti-transferrin receptor scFv-immunoliposomes","volume":"1","author":"Xu","year":"2002","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0930","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/mt.2013.32","article-title":"Phase I study of a systemically delivered p53 nanoparticle in advanced solid tumors","volume":"21","author":"Senzer","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0935","doi-asserted-by":"crossref","first-page":"6175","DOI":"10.1016\/j.biomaterials.2013.04.056","article-title":"Suppression of pancreatic tumor growth by targeted arsenic delivery with anti-CD44v6 single chain antibody conjugated nanoparticles","volume":"34","author":"Qian","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2015.05.003_bb0940","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1056\/NEJM199811053391901","article-title":"Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide","volume":"339","author":"Soignet","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0945","doi-asserted-by":"crossref","first-page":"e114","DOI":"10.1097\/MPA.0b013e3181a0b6f2","article-title":"A novel combination therapy with arsenic trioxide and parthenolide against pancreatic cancer cells","volume":"38","author":"Wang","year":"2009","journal-title":"Pancreas"},{"key":"10.1016\/j.jconrel.2015.05.003_bb0950","first-page":"5432","article-title":"Tumor growth inhibition by arsenic trioxide (As2O3) in the orthotopic metastasis model of androgen-independent prostate cancer","volume":"61","author":"Maeda","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0955","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.3892\/ol.2012.611","article-title":"The expression levels of CD44v6 are correlated with the invasiveness of hepatocellular carcinoma in vitro, but do not appear to be clinically significant","volume":"3","author":"Mima","year":"2012","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0960","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S0046-8177(98)80014-2","article-title":"CD44V6 expression in human colorectal carcinoma","volume":"29","author":"Coppola","year":"1998","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0965","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/jso.10082","article-title":"Expression of CD44v6 in advanced gastric cancer and its relationship to hematogenous metastasis and long-term prognosis","volume":"79","author":"Yamaguchi","year":"2002","journal-title":"J. Surg. Oncol."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0970","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.3892\/or.2013.2273","article-title":"CD44v6 expression is related to mesenchymal phenotype and poor prognosis in patients with colorectal cancer","volume":"29","author":"Saito","year":"2013","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0975","doi-asserted-by":"crossref","first-page":"3","DOI":"10.14712\/fb2005051010003","article-title":"Expression of CD44v6 correlates with cell proliferation and cellular atypia in urothelial carcinoma cell lines 5637 and HT1197","volume":"51","author":"Kuncov\u00e1","year":"2005","journal-title":"Folia Biol. (Praha)"},{"key":"10.1016\/j.jconrel.2015.05.003_bb0980","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1007\/s00262-010-0819-z","article-title":"Generation of a stable anti-human CD44v6 scFv and analysis of its cancer-targeting ability in vitro","volume":"59","author":"Chen","year":"2010","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.jconrel.2015.05.003_bb0985","doi-asserted-by":"crossref","first-page":"9480","DOI":"10.1021\/nn202410f","article-title":"Targeted delivery of cisplatin to lung cancer using ScFvEGFR-heparin-cisplatin nanoparticles","volume":"5","author":"Peng","year":"2011","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2015.05.003_bb0990","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/smll.200800714","article-title":"Single chain epidermal growth factor receptor antibody conjugated nanoparticles for in vivo tumor targeting and imaging","volume":"5","author":"Yang","year":"2009","journal-title":"Small"},{"key":"10.1016\/j.jconrel.2015.05.003_bb0995","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S0169-409X(02)00026-1","article-title":"PEGylated antibodies and antibody fragments for improved therapy: a review","volume":"54","author":"Chapman","year":"2002","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2015.05.003_bb1000","doi-asserted-by":"crossref","first-page":"4368","DOI":"10.1016\/j.biomaterials.2014.01.076","article-title":"PEGylated liposomes with NGR ligand and heat-activable cell-penetrating peptide-doxorubicin conjugate for tumor-specific therapy","volume":"35","author":"Yang","year":"2014","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2015.05.003_bb1005","doi-asserted-by":"crossref","first-page":"6732","DOI":"10.1158\/0008-5472.CAN-05-4199","article-title":"Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models","volume":"66","author":"Kirpotin","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2015.05.003_bb1010","doi-asserted-by":"crossref","first-page":"15549","DOI":"10.1073\/pnas.0707461104","article-title":"Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging","volume":"104","author":"Bartlett","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2015.05.003_bb1015","doi-asserted-by":"crossref","first-page":"8495","DOI":"10.1073\/pnas.150228297","article-title":"High-resolution microPET imaging of carcinoembryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragment","volume":"97","author":"Wu","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2015.05.003_bb1020","first-page":"1962","article-title":"124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice","volume":"44","author":"Sundaresan","year":"2003","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jconrel.2015.05.003_bb1025","doi-asserted-by":"crossref","first-page":"11631","DOI":"10.1158\/0008-5472.CAN-05-1093","article-title":"Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo","volume":"65","author":"Mamot","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2015.05.003_bb1030","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1158\/1535-7163.MCT-07-0615","article-title":"Antitumor activity of an epithelial cell adhesion molecule targeted nanovesicular drug delivery system","volume":"6","author":"Hussain","year":"2007","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.jconrel.2015.05.003_bb1035","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.drudis.2009.10.009","article-title":"Synthetic therapeutic peptides: science and market","volume":"15","author":"Vlieghe","year":"2010","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jconrel.2015.05.003_bb1040","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1089\/153685904774129711","article-title":"Establishment and evaluation of cancer-specific human monoclonal antibody GAH for targeting chemotherapy using immunoliposomes","volume":"23","author":"Hosokawa","year":"2004","journal-title":"Hybrid. Hybridomics"},{"key":"10.1016\/j.jconrel.2015.05.003_bb1050","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1021\/pr401015b","article-title":"Common glycoproteins expressing polylactosamine-type glycans on matched patient primary and metastatic melanoma cells show different glycan profiles","volume":"13","author":"Kinoshita","year":"2014","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.jconrel.2015.05.003_bb1070","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1200\/JCO.2000.18.4.904","article-title":"Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin","volume":"18","author":"Baselga","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2015.05.003_bb1080","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1158\/1078-0432.CCR-06-2218","article-title":"Potent siRNA inhibitors of ribonucleotide reductase subunit RRM2 reduce cell proliferation in vitro and in vivo","volume":"13","author":"Heidel","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2015.05.003_bb1085","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3389\/fonc.2013.00190","article-title":"Nanocarrier-mediated targeting of tumor and tumor vascular cells improves uptake and penetration of drugs into neuroblastoma","volume":"3","author":"Pastorino","year":"2013","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jconrel.2015.05.003_bb1090","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.ejca.2003.10.011","article-title":"Anticancer drug response and expression of molecular markers in early-passage xenotransplanted colon carcinomas","volume":"40","author":"Fichtner","year":"2004","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.jconrel.2015.05.003_bb1095","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/nrclinonc.2012.61","article-title":"Patient-derived tumour xenografts as models for oncology drug development","volume":"9","author":"Tentler","year":"2012","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2015.05.003_bb1100","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1089\/hum.2013.209","article-title":"A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer","volume":"25","author":"Abate-Daga","year":"2014","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.jconrel.2015.05.003_bb1105","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/clpt.2008.200","article-title":"Direct in vivo xenograft tumor model for predicting chemotherapeutic drug response in cancer patients","volume":"85","author":"Rubio-Viqueira","year":"2009","journal-title":"Clin. Pharmacol. Ther."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365915003016?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365915003016?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T20:45:19Z","timestamp":1748378719000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365915003016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":216,"alternative-id":["S0168365915003016"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2015.05.003","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2015,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New trends in guided nanotherapies for digestive cancers: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2015.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}